Biobijou
Biobijou is a South Korean K-beauty bio and medical aesthetics manufacturer producing HA dermal fillers, LNP-enabled skin boosters, botulinum toxin, and regenerative injectables, sold globally through direct B2B sales to clinics and a distributor network across 21 countries, with China as the largest market.
- Company typePublic
- Founded2018
- HeadquartersHanam, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biobijou does
Biobijou is a South Korea-based K-beauty bio and medical aesthetics manufacturer that develops, produces, and globally distributes injectable aesthetic products. Its portfolio spans hyaluronic acid dermal fillers (COLENA, CANDORLOV), LNP-enabled skin boosters (ASCENART series), botulinum toxin products (ELLELUX), fat reduction injectables (MIWELL), and ECM-based regenerative boosters (Celivion Lin J). The company's differentiation rests on proprietary Lipid Nanoparticle (LNP) delivery technology, patented high/low molecular weight HA cross-linking manufacturing methods, and Allo-PELT low-temperature ECM processing, all produced at its GMP-certified Hanam facility capable of 200,000+ syringes per month (50,000 own brand plus 100,000 OEM).
The business operates a vertically integrated B2B model, selling directly to aesthetic clinics, dermatologists, and plastic surgery hospitals and through country-level distributors across 11-21 countries including China, Vietnam, Thailand, Brazil, the Middle East, CIS, and Europe. China is the largest market, served via four owned branch offices and a Key Doctor network that has driven over 600,000 filler unit sales. Pricing is quote-based under multi-year B2B contracts, with no public disclosure. Distribution is supplemented by major Korean pharma vendor relationships (Daewoong, Daehan Newpharm, Medytox, Hugel) for botulinum toxin and complementary product lines.
Biobijou generates revenue through medical device sales (fillers, boosters, botulinum toxin), cosmetic product sales, and OEM/contract manufacturing for external brands. Strategic alliances extend its technology base, including exclusive China distribution of Exocobio's ASCEplus exosome regenerative product, joint LNP-filler development with Moojin Medi, and PN/PDRN technology collaboration with Zerone Bio. The company is majority-owned (65%) by Cheongdam Global and completed its KOSDAQ listing on May 20, 2025.
Biobijou firmographics
Firmographics- Name
- Biobijou
- Legal name
- (주)바이오비쥬
- Website
- https://biobijou.co.kr
- Company type
- Public
- Founded year
- 2018
- Headcount range
- 11–50 employees
- Short description
- Biobijou is a South Korean K-beauty bio and medical aesthetics manufacturer producing HA dermal fillers, LNP-enabled skin boosters, botulinum toxin, and regenerative injectables, sold globally through direct B2B sales to clinics and a distributor network across 21 countries, with China as the largest market.
- Ownership category
- akta.pro rank
Biobijou industry classification
Industry- Product category
- Medical Aesthetic Devices
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
- akta.pro secondary industries
- Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB), Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
Keywords
Where Biobijou is headquartered
LocationHeadquarters
- HQ city
- Hanam
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
Biobijou business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Aesthetic Product Sales: Development, manufacture, and sale of medical aesthetic products including hyaluronic acid dermal fillers (COLENA, CANDORLOV), skin boosters (ASCENART series), and botulinum toxin products (ELLELUX, EleLuxe). Products are sold globally through direct export and distributor networks. GMP-certified manufacturing facility in Hanam with capacity of 200,000+ syringes per month.
- Cosmetic Product Sales: Sale of cosmetic products including fat reduction/lipolysis injectables (MIWELL series), sheet masks, and topical skincare under brands CANDORLOV and ASCENART. Sold through the same global distribution network as medical devices.
- OEM/Contract Manufacturing: Biobijou offers OEM manufacturing services for external brands. Factory CAPA is stated at 150,000 units per month total, with 50,000 units for own brands and 100,000 units for OEM production.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B pricing for medical aesthetic products sold to aesthetic clinics and distributors |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Biobijou product offering
Product offeringCore offering
Biobijou develops, manufactures, and globally distributes medical aesthetic devices including hyaluronic acid (HA) dermal fillers (COLENA, CANDORLOV), LNP-technology skin boosters (ASCENART series), botulinum toxin products (ELLELUX), ECM boosters (Celivion Lin J), and fat reduction injectables (MIWELL). The company operates a vertically integrated model with its own GMP-certified manufacturing facility in Hanam, South Korea, exporting to over 11 countries with a strong direct presence in China via 4 branch offices.
Differentiator
Problem solved
Functional benefit
Products and services
- COLENA Hyaluronic acid-based dermal filler for facial contouring, wrinkle reduction, and lip augmentation. Used by aesthetic clinics and dermatologists for volume restoration procedures. Obtained European CE certification and Korean MFDS export approval.
- CANDORLOV (series) Hyaluronic acid dermal filler series with high elasticity, uniformity, and low BDDE residue below standard values. Used by medical professionals for aesthetic injectable procedures including facial volume restoration.
- ASCENART series (Fillmoa, Lux, Aqua, Nanofill, Amber) Skin booster injectable product line incorporating LNP (Lipid Nano Particle) delivery technology for enhanced ingredient penetration into skin cells. Used for hydration, skin rejuvenation, and collagen formation. Includes Fillmoa, Lux, Aqua, Nanofill, and Amber variants.
- Celivion Lin J ECM (Extracellular Matrix) booster injectable product utilizing Allo-PELT low-temperature processing technology that minimizes thermal denaturation and preserves ECM structure. Used for tissue reconstruction and skin regeneration.
- ELLELUX / EleLuxe Botulinum toxin injectable product used for wrinkle reduction, hyperhidrosis treatment, and other aesthetic procedures requiring botulinum toxin applications. Sold through the global distribution network alongside medical devices.
- MIWELL series Fat reduction/lipolysis injectable products for body contouring procedures. Sold through the same global distribution network as medical devices and used by aesthetic clinics.
- ASCEplus™ Exosome-based regenerative aesthetic skin booster product exclusively distributed by Biobijou in the Chinese market under supply agreement with Exocobio. World-first exosome regenerative aesthetic technology. Won the IR52 Jang Young-sil Award in 2021.
- OEM Contract Manufacturing Contract manufacturing services for external brands, utilizing GMP-certified automated production lines. Dedicated OEM capacity of 100,000 units per month on top of 50,000 units for own brands. Enables external brands to leverage Biobijou's manufacturing infrastructure, automated prefilled syringe packaging, and quality management systems.
Quantifiable outcome
- Over 600,000 dermal filler units sold in China alone
- +3 more outcomes
Companies that use Biobijou
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Biobijou technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Biobijou partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Moojin Medi (무진메디)coreBiobijou and Moojin Medi signed a strategic MOU for joint development of next-generation LNP-based dermal fillers (working title). Moojin Medi brings nano material technology and research capabilities; Biobijou contributes medical device technology development and marketing expertise. LNP is a lipid nanoparticle delivery system commonly used in mRNA vaccines for protecting and delivering active ingredients to target cells. The partnership aims to develop functional medical devices using LNP materials as key raw ingredients.
- Zerone Bio (제론바이오)coreZerone Bio, Cheongdam Global, and Biobijou entered a comprehensive strategic MOU covering PN filler development and distribution, cosmeceutical product development and distribution, inner beauty product development and distribution, and other biotech new material development focused on overseas markets. Zerone Bio specializes in PDRN (PolyDeoxyRiboNucleotide) production from salmon reproductive cells and PN (Polynucleotide) technology for skin regeneration and collagen production. The three companies aim to maximize synergies in technology and marketing to enhance K-Beauty's global position.
- Exocobio (엑소코바이오)coreBiobijou signed an exclusive supply agreement with Exocobio for ASCEplus™ (Advanced Skincare Complex for Everyone), a world-first exosome-based regenerative aesthetic product, for the Chinese market. Exocobio supplies the ASCEplus™ products and Biobijou handles exclusive distribution in China. Exocobio holds patented exosome separation technology (ExoSCRT™) and freeze-drying technology (ExoLyo™), and was featured in Nature Biotechnology as the only Asian exosome company.
- Major Vendor Partners (Daewoong Pharmaceutical, Daehan Newpharm, Medytox, Hugel)minorBiobijou signed major vendor agreements with leading Korean pharmaceutical and medical aesthetic companies including Daewoong Pharmaceutical (대웅제약), Daehan Newpharm (대한뉴팜), Medytox (메디톡스), and Hugel (휴젤) in 2018 for the supply and distribution of botulinum toxin and other aesthetic product lines. Also signed a distributor contract with PharmaResearch (파마리서치) for product distribution.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Biobijou competitors and assessment
Company assessmentDirect peers
- Revance Therapeutics: Aesthetics company with botulinum toxin (Daxxify) and HA filler portfolio. Comparable to Biobijou as a science-led, technology-differentiated injectable aesthetics player pursuing global expansion.
- Croma-Pharma: Austrian aesthetics manufacturer (Princess HA fillers, botulinum toxin). Comparable mid-sized European-headquartered injectable aesthetics company with OEM/own-brand manufacturing and global distribution profile similar to Biobijou.
- Evolus: U.S.-listed aesthetics company focused on botulinum toxin (Jeuveau). Directly comparable to Biobijou's ELLELUX franchise as a focused, brand-driven neurotoxin challenger competing against incumbents on differentiated positioning.
- Bloomage Biotechnology: Chinese HA-based biotechnology company (Hyron, BM Muscle) with both consumer skincare and medical device injectables. Comparable to Biobijou in HA manufacturing, China-market access, and ingredient-to-device vertical integration.
- Sinclair Pharma: European aesthetics company (now part of Huadong Medicine) with HA fillers and biostimulators. Comparable mid-sized international aesthetics manufacturer/distributor with global distribution ambitions similar to Biobijou's.
- Hugel: Major Korean aesthetics company producing botulinum toxin (Botulax) and hyaluronic acid fillers. Direct competitor to Biobijou across the same product categories and Korean/Asian markets, with much larger global commercial scale.
- Medytox: Korean botulinum toxin developer (Neuronox) and emerging aesthetics player. Direct peer to Biobijou in the injectable aesthetics category with overlapping distribution and a similar export-oriented Korean manufacturer profile.
Broad incumbents
- Galderma: Global pure-play dermatology/aesthetics company (Restylane, Sculptra, Dysport). Largest HA filler competitor worldwide and a broad incumbent that sets pricing and regulatory benchmarks Biobijou must meet across CE, FDA, and Asian markets.
- AbbVie (Allergan Aesthetics): Owner of Botox and the Juvederm filler family, the global benchmark in aesthetic injectables. Defines the premium pricing tier and clinical-evidence expectations Biobijou's HA filler and botulinum toxin SKUs must position against.
- Daewoong Pharmaceutical: Large Korean pharmaceutical company with a major aesthetics franchise (Nabota botulinum toxin, dermal fillers). A broader incumbent that both competes with and distributes through Biobijou; comparable in HA filler and botulinum toxin categories.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biobijou social profiles
Digital presenceBiobijou financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biobijou leadership team
Management profileNumber of profiles
Profiles2 records
Biobijou funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biobijou M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biobijou
What does Biobijou do?
Biobijou develops, manufactures, and globally distributes medical aesthetic devices including hyaluronic acid (HA) dermal fillers (COLENA, CANDORLOV), LNP-technology skin boosters (ASCENART series), botulinum toxin products (ELLELUX), ECM boosters (Celivion Lin J), and fat reduction injectables (MIWELL). The company operates a vertically integrated model with its own GMP-certified manufacturing facility in Hanam, South Korea, exporting to over 11 countries with a strong direct presence in China via 4 branch offices.
Is Biobijou a public or private company?
Biobijou is a public company. It is classified as public.
When was Biobijou founded?
Biobijou was founded in 2018. It employs 11 to 50 people.
Where is Biobijou based?
Biobijou is headquartered in Hanam, South Korea, in the Asia region.
How does Biobijou make money?
Three revenue lines are on record. Medical Aesthetic Product Sales are the primary driver. The others are cosmetic Product Sales and OEM/Contract Manufacturing.
Who are Biobijou's main competitors?
Direct peers on record are Revance Therapeutics, Croma-Pharma, Evolus, Bloomage Biotechnology, Sinclair Pharma, Hugel and Medytox. Broad incumbents are Galderma, AbbVie (Allergan Aesthetics) and Daewoong Pharmaceutical.
Does Biobijou have an API?
No public API is recorded for Biobijou.
What industry is Biobijou in?
Biobijou's product category is Medical Aesthetic Devices. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAAAKAB, Drug Product Fill-Finish & Aseptic Manufacturing Services. Its NAICS code is 325412 and its SIC code is 2834.